Mainz Biomed NV announces the commercial launch of ColoAlert in Poland, made possible through a strategic collaboration with testDNA Sp. z o. o. Sp. K (?testDNA?).

The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (?CRC?). ColoAlert, Mainz Biomed's product is a user-friendly and highly effective at-home screening test able to help meaningfully address the pressing global challenge of early colorectal cancer detection. The strategic alliance with testDNA aims to extend the reach of this transformative technology, providing improved access to screening tools that come with the potential to save countless lives across Poland.

Operating since 2003, testDNA is a national leader in the field of DNA-based testing services. As an accredited research laboratory sanctioned by the Polish Center for Accreditation, the laboratory is headquartered in Katowice, Poland, and boasts an expansive network of over 300 collection points throughout the country. With a comprehensive portfolio, testDNA is renowned for delivering genetic-based testing solutions tailored to individual needs.

The urgency for alternative CRC screening options is underscored by data from the World Cancer Research Fund International which ranked Poland 7th (seventh) in the world for the highest mortality rate. With over 21 million people aged over 40, the market opportunity for ColoAlert is significant, especially as there has been a low level of national participation in CRC screening which traditionally has been colonoscopies. In the recently published NordICC study in the New England Journal of Medicine, only 33% of those invited to participate in colonoscopy screening actually took part.

This highlights the need to have alternative screening options that are less invasive and easier to perform at home.